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Abstract Tumor necrosis factor-K (TNF-K) activates extra-
cellular-regulated kinases (ERKs) and p38 mitogen-activated
protein kinase (p38MAPK), and inhibits the expression of
uncoupling protein-1 (UCP-1) and adipocyte-specific genes in
rat fetal brown adipocytes. MEK inhibition with PD98059
abolished the inhibitory effect of TNF-K on UCP-1, but not on
adipogenic genes. In contrast, inhibition of p38MAPK with
SB203580 potentiated the negative effect of TNF-K on UCP-1
and adipogenic genes. The inhibitory action of TNF-K was
partially correlated with changes in C/EBPK and L protein levels
and in their DNA binding activity, suggesting a role for these
transcription factors. However, other transcription factors might
explain the different regulation of UCP-1 and adipogenic genes
by ERKs. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Brown adipose tissue (BAT) is specialized in heat produc-
tion by the mechanism called ‘non-shivering thermogenesis’.
This process is carried out by the uncoupling protein-1 (UCP-
1), present in the mitochondrial inner membrane, which al-
lows dissipation of energy from substrate oxidation as heat
[1]. BAT is activated during the perinatal period, after cold
exposure or after feeding with a ‘cafeteria’ diet [1].
Tumor necrosis factor-K (TNF-K) has recently been pro-
posed to be responsible for BAT apoptosis, altered cellular
morphology, and reduction in the L3-adrenergic receptors
and UCP-1 expression observed in obese (ob/ob) mice, since
those BAT abnormalities were lost in mice lacking TNF-K
receptors [2]. TNF-K might also be relevant in the control of
the number of brown adipocytes during the fetal period and/
or in the involution of BAT produced after weaning, since it
inhibits cell growth and induces apoptosis in fetal brown adi-
pocytes [3]. In addition, TNF-K could also contribute to the
negative regulation of BAT by a direct inhibition of the ther-
mogenic and adipogenic di¡erentiation, not related with the
induction of insulin resistance by impairing insulin signaling
[4]. TNF-K could do it through activation of di¡erent signal-
ing pathways such as extracellular-regulated kinases (ERKs)
(p44/p42 mitogen-activated protein kinases (MAPKs)), JNKs,
p38MAPKs or NF-UB [5^8].
ERKs are activated by di¡erent extracellular signals [7^9],
including cytokines, and regulate proliferation, di¡erentiation
and apoptosis (review in [9]). On the other hand, the p38
subfamily of MAPKs, which includes p38K, p38L, p38L2,
p38Q (ERK6/SAPK3) and p38N (review in [9]), was initially
associated with stress responses, having been identi¢ed
p38KMAPK as a stress-induced kinase [10]. However,
p38MAPKs can mediate di¡erent cellular functions such as
di¡erentiation, or developmental processes (review in [11]).
Thus, in mice lacking p38KMAPK, placental development is
impaired [12]. p38MAPK is also required for the insulin-in-
duced adipocytic di¡erentiation of 3T3-L1 cells [13,14], induc-
ing apoptosis [14].
In rat fetal brown adipocytes, p38MAPK mediates TNF-K-
induced growth inhibition and apoptosis, whereas ERKs play
the opposite role [15]. ERKs are also essential mediators of
the IGF-I/insulin and noradrenaline-induced proliferation,
while attenuating the di¡erentiation process [16,17] as they
do in the insulin-induced di¡erentiation of 3T3-L1 cells [18].
We analyze here the direct inhibitory e¡ect of TNF-K on the
thermogenic and/or adipocytic di¡erentiation of brown adipo-
cytes and the role played by p38 and ERKs.
2. Materials and methods
2.1. Isolation of fetal brown adipocytes and culture
Brown adipocytes from 20 day old rat fetuses were isolated as
described [19] and maintained in primary culture. Cells were grown
in minimum essential medium supplemented with 10% fetal bovine
serum for 24 h. Then, cells were serum-starved overnight and main-
tained in the absence or presence of TNF-K (10 ng/ml), IGF-I
(2.5 nM) or combinations of them for di¡erent time periods as in-
dicated. To inhibit ERKs, cells were pretreated with the MEK1
inhibitor PD98059 (Calbiochem #513000) at 20 WM for 1 h. Similarly,
to inhibit p38MAPK, cells were pretreated with SB203580 at
5 WM from Calbiochem (#559389) or PD169316 (#513030) at
400 nM.
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2.2. Western blot analysis
Active ERK (ERK1/2) levels were quanti¢ed in total cell extracts
by Western blot analysis using an anti-phospho-ERKs antibody from
New England Biolabs (#9101S) and total ERK levels with the anti-
ERK1/2 antibody from UBI (06-182) as described [17]. Similarly,
active p38MAPK was quanti¢ed using an anti-phospho-p38MAPK
antibody from New England Biolabs (#9211S), and total
p38MAPK levels with an anti-p38MAPKK antibody from Santa
Cruz (#sc-535) [15].
CAAT enhancer binding protein (C/EBP) K and L were also quan-
ti¢ed in total cell extracts by Western blot analysis, using C/EBPK-
(sc-61) and C/EBPL- (sc-150) speci¢c antibodies from Santa Cruz.
Blots were developed using the ECL system (Amersham).
2.3. MAPKAPK2 kinase assay
MAPKAPK2 kinase activity was assayed in immunocomplexes,
prepared with an anti-MAPKAPK2 antibody from StressGen Bio-
technologies Corp. (#KAP-MA015E) as described [15], and human
recombinant Hsp27 protein (StressGen Biotechnologies Corp. #SPP-
715) was used as substrate. Phosphorylated Hsp27 was visualized by
autoradiography.
2.4. RNA extraction and Northern blot analysis
Northern blot analysis and total RNA extraction were performed
as previously described [17]. Blots were hybridized with probes for
UCP-1 [20], fatty acid synthase (FAS) [21] and malic enzyme [22]
and, then, reproved with 18S ribosomal probe to normalize. Radio-
activity was quanti¢ed in a Fuji-Film BAS-1000 apparatus.
2.5. Gel mobility shift assays
C/EBP mobility shift assays were performed using nuclear extracts
as described [15], using a speci¢c double-stranded oligonucleotide cor-
responding to the NF-IL6 site of the COX2 promoter: 5P-GGGTAT-
TATGCAATTGGAAG-3P.
2.6. Statistical analysis
Statistical analysis of the results was done using the Student’s t test.
3. Results
3.1. TNF-K activates ERKs and p38MAPK.
Inhibition by PD98059 and SB203580, respectively
TNF-K activated ERKs, in the absence or presence of IGF-
I (Fig. 1A). IGF-I, as previously described [17], also activated
ERKs. This TNF-K-induced activation was totally prevented
by pretreatment with the MEK inhibitor, PD98059 (Fig. 1A).
p38MAPK was also activated by TNF-K, in the absence or
presence of IGF-I, but not by IGF-I (Fig. 1B). MAPKAPK2,
one of the p38MAPK downstream targets, was also activated
by TNF-K (Fig. 1C), and this activation was blocked by pre-
treatment with the speci¢c p38MAPK inhibitor SB203580
(Fig. 1C).
3.2. TNF-K inhibits brown adipocytes di¡erentiation.
Regulation by ERKs and p38MAPK
Next, we studied whether TNF-K played a direct role in-
hibiting the expression of UCP-1 and adipogenic genes in
brown adipocytes, and the involvement of ERKs and
p38MAPK, using the speci¢c inhibitors, PD98059 and
SB203580, respectively. TNF-K decreased basal and IGF-I
induced UCP-1 mRNA expression (Fig. 2A) as well as FAS
and malic enzyme mRNA levels (Fig. 2B). Pretreatment with
PD98059 totally reverted the inhibitory e¡ect of TNF-K on
UCP-1 and enhanced the expression induced by IGF-I (Fig.
2A). However, the TNF-K-induced downregulation of adipo-
cyte-speci¢c mRNAs, FAS and malic enzyme, was not pre-
vented, although their levels were always higher in cells pre-
treated with PD98059 (Fig. 2B). So, the upregulation of
adipocyte-speci¢c genes by MEK inhibition was only signi¢-
cant when IGF-I was present. Di¡erent from this, pretreat-
ment with SB203580 enhanced the inhibitory e¡ect of TNF-K
on UCP-1, FAS and malic enzyme mRNAs expression, either
in control or IGF-I-treated cells (Fig. 3). These results were
con¢rmed using PD169316, another p38 inhibitor (not
shown). Furthermore, data from FAS and malic enzyme
mRNA measurements were con¢rmed by cytometric analysis
of lipid content after staining with Nile red under all the
conditions studied (not shown), and data from UCP-1
mRNA quanti¢cations by Western blot analysis of UCP-1
(not shown).
3.3. TNF-K decreases C/EBPs protein expression and DNA
binding activity. Regulation by ERKs and p38MAPK
C/EBP transcription factors are known positive regulators
of the adipocytic (review in [23,24]) and thermogenic di¡er-
entiation (review in [24]). Thus, we studied the e¡ect of TNF-K
on C/EBP DNA binding ability, and on the levels of C/EBP
proteins, and the role played by ERKs and p38.
Treatment with TNF-K for 24 h highly reduced the binding
of nuclear proteins to an oligonucleotide probe corresponding
to the C/EBP consensus site (Fig. 4A). Inhibition of p38 with
Fig. 1. TNF-K, either in the presence or absence of IGF-I, activates
ERKs and p38MAPK pathways in rat fetal brown adipocytes. Inhi-
bition by PD98059 and SB203580, respectively. Serum-starved cells
were triggered with IGF-I, TNF-K or both for 10 min. When indi-
cated, they were pretreated with PD98059, or with SB203580.
(A) ERKs activity and inhibition by PD98059. Upper panel and
lower panel, representative phospho-ERK1/2 and total ERK1/2
Western blots, respectively. (B) p38MAPK activity. Upper panel
and lower panel, representative phospho-p38MAPK and total
p38MAPK Western blots, respectively. (C) MAPKAPK2 activity in
immunocomplexes and inhibition by SB203580. Representative auto-
radiogram showing phospho-Hsp27.
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Fig. 2. Role played by ERKs in the TNF-K-induced decrease in
UCP-1, malic enzyme and FAS mRNA levels in rat fetal brown
adipocytes. Serum-starved cells, pretreated with PD98059 or non-
pretreated as indicated, were triggered with IGF-I, TNF-K or both
for 48 h, or maintained untreated. Representative Northern blot
analysis of UCP-1 (A), malic enzyme (ME) and FAS mRNAs (B),
and fold increase of these mRNAs normalized with 18S ribosomal
probe. Results are means þ S.E.M. of four independent experiments.
Statistical analysis was carried out by Student’s t test. *P6 0.05,
**P6 0.01, ***P6 0.001 as compared with control; P6 0.01 as
compared with TNF-K-treated cells; 3P6 0.05, 333P6 0.001 as com-
pared with IGF-I-treated cells ; 4P6 0.05, 44P6 0.01 as compared
with cells treated with hIGF-I plus TNF-K.
Fig. 3. p38MAPK plays a positive role in the regulation of UCP-1,
malic enzyme and FAS mRNA levels by TNF-K in rat fetal brown
adipocytes. Serum-starved cells, pretreated with SB203580 or non-
pretreated as indicated, were triggered with IGF-I, TNF-K or both
for 48 h, or maintained untreated. Representative Northern blot
analysis of UCP-1 (A), and malic enzyme (ME) and FAS mRNAs
(B), and fold increase of these mRNAs normalized with 18S riboso-
mal probe. Results are means þ S.E.M. of four independent experi-
ments. Statistical analysis was carried out by Student’s t test.
*P6 0.05, **P6 0.01, ***P6 0.001 as compared with control;
P6 0.05, P6 0.01 as compared with TNF-K-treated cells ;
3P6 0.05, 33P6 0.01, 333P6 0.001 as compared with IGF-I-treated
cells ; 4P6 0.05 as compared with cells treated with IGF-I plus
TNF-K.
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SB203580 enhanced this e¡ect, while ERKs inhibition with
PD98059 partially reversed it (Fig. 4A). In supershift assays,
incubation with anti-C/EBPL eliminated most of the binding
to the C/EBP site (Fig. 4A), and incubation with an K-speci¢c
antibody decreased this binding, too, showing that C/EBPK
and L proteins bound this C/EBP sequence. C/EBPN did not
bind (not shown).
Changes in the binding of nuclear proteins to a C/EBP site
can re£ect changes in the levels of C/EBP proteins. So, we
measured C/EBPK, L and N protein levels by Western blot.
Fig. 4B shows a reduction in the levels of p35 C/EBPL, and
p42 and p30 C/EBPK after 24 h of TNF-K treatment. This
e¡ect was potentiated by SB203580, whereas it was prevented
by PD98059 (Fig. 4B). C/EBPN protein levels did not change
under these conditions (not shown).
4. Discussion
TNF-K has been shown to be a potent inhibitor of the
insulin-induced adipocyte-speci¢c gene expression in white
and brown adipocytes (review in [25]). Some of these TNF-K
e¡ects are due to the impairment of the insulin signaling,
which leads to insulin resistance in white [25] and brown adi-
pocytes [4,25]. A direct e¡ect of TNF-K inhibiting the expres-
sion of some adipogenic genes has also been described in white
adipocytes (review in [25]). However, a direct e¡ect of TNF-K
inhibiting thermogenic and adipogenic di¡erentiation of
brown adipocytes had not been found until now.
p38MAPK was shown to be required for the insulin-in-
duced adipocytic di¡erentiation of 3T3-L1 cells [13,14]. We
have now seen that in brown adipocytes p38 also mediates
this action in response to TNF-K, an inhibitor of adipogene-
sis. In addition, we have found a new role for p38 as a pos-
itive regulator of UCP-1 expression, upon TNF-K stimulation.
This positive regulation of brown adipocytes di¡erentiation by
p38 appears to be mediated through the upregulation of
C/EBPK and L. This might be related to the mechanism de-
scribed for 3T3-L1 cells induced to di¡erentiate by insulin,
where p38MAPK mediated phosphorylation of C/EBPL, lead-
ing to an increase of its transcriptional activity, that could be
responsible for the p38-dependent expression of peroxisome
proliferator activator receptor Q (PPARQ) [13,14]. However,
our results are di¡erent from those suggesting that p38 might
be a negative regulator of 3T3-L1 di¡erentiation [26]. These
suggestions were based on the ability of p38MAPK to phos-
phorylate CHOP (GADD153), whose overexpression blocked
3T3-L1 di¡erentiation but not that of a mutant unable to be
phosphorylated by p38 [26]. This apparent contradiction
could be originated by the fact that under our conditions,
CHOP protein levels are very low [15], while C/EBPK and L
are much more abundant, and, therefore, p38 might preferen-
tially phosphorylate C/EBPL instead of CHOP, leading to
adipocytic di¡erentiation.
ERKs appear to mediate the inhibitory e¡ect of TNF-K on
the thermogenic marker, UCP-1, but not on lipogenic markers
Fig. 4. Regulation of C/EBPK/L protein levels and their DNA bind-
ing activity by TNF-K in rat fetal brown adipocytes. Role played
by ERKs and p38MAPK. Serum-starved cells, pretreated with
PD98059, SB203580 or non-pretreated as indicated, were triggered
with TNF-K for 24 h or maintained untreated. (A) C/EBP DNA
binding activity. Middle panel, representative gel-shift assay; lower
panel, representative supershift assay of control cells, in the absence
of C/EBP antibodies, or with either C/EBPK and/or L antibodies;
upper panel, fold increase of C/EBP binding activity. (B) C/EBPK
and L protein levels. Lower panel, C/EBPK Western blot analysis
showing p42 and p30 C/EBPK proteins; middle panel, C/EBPL
Western blot analysis showing p38 and p35 C/EBPL ; upper panel,
fold increase of p35 C/EBPL, and p42 and p30 C/EBPK protein lev-
els. Results are means þ S.E.M. of three independent experiments.
Statistical analysis was carried out by Student’s t test. **P6 0.01 as
compared with control; P6 0.05 as compared with TNF-K-treated
cells.
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as seen in 3T3-L1 cells [27], although ERKs are also negative
regulators in this case. This e¡ect might be related with the
decrease in the levels of C/EBPK and L, in their binding to
DNA or even with PPARQ phosphorylation. Thus, PPARQ,
which is another transcription factor that activates the expres-
sion of adipogenic genes [23,28,29] and the UCP-1 gene [28^
30], seemed to be phosphorylated in response to TNF-K (data
not shown) through ERKs as it occurs in 3T3-L1 cells treated
with insulin [31]. However, all these transcription factors bind
to the regulatory sequences of UCP-1 and those of many
adipogenic genes, inducing their expression. Hence, these
changes in C/EBPs and PPARQ appeared not to be su⁄cient
by themselves to explain why TNF-K-induced downregulation
of UCP-1 was reverted by inhibition of ERKs, while that of
adipogenic genes was not. So, we analyzed the possibility that
c-Jun, whose mRNA is upregulated via ERKs [15], would be
inhibiting UCP-1 expression through binding to the proximal
cAMP regulatory element (CRE) region of its promoter [32].
However, no change was found at this level (not shown),
probably because of the high levels of phospho-CRE binding
protein (CREB) present in the cells [15]. Thus, CREB, instead
of c-Jun, would bind to this CRE site in the UCP-1 promoter
[32]. Hence, the di¡erent regulation of UCP-1 by TNF-K
through ERKs might be due to other causes and it could be
related with the action of coactivators and/or other transcrip-
tion factors. Thus, in the case of PPARQ, that is essential for
the function of the UCP-1 enhancer [30,33], its e¡ect is
strongly increased by binding of the coactivator, PGC-1
(PPARQ coactivator-1), through a ligand-independent way
[30,34,35]. As it binds to the region of PPARQ phosphorylated
by ERKs [34], this binding could be impaired, leading to in-
hibition of UCP-1 expression. PGC-1 is expected to be highly
expressed under our experimental conditions, for it is tran-
scriptionally upregulated by CREB [30], which is present in
high levels [15]. In contrast, regarding adipogenic genes,
although ERKs-mediated PPARQ phosphorylation can play
a negative role, as suggested by the e¡ect of overexpression
of a PPARQ mutant not phosphorylated by ERKs [31], the
interaction between PPARQ and the adipogenic cofactor
PGC-2 is not a¡ected by this phosphorylation [36]. In addi-
tion, other transcription factors that activate adipogenesis
might be regulated by TNF-K through ERKs-independent
pathways. Hence, a decrease in the levels of ADD1/SREBP-
1 (adipocyte di¡erentiation and determination factor-1/sterol
regulatory element binding protein 1) in response to TNF-K
might be possible, impairing its positive e¡ect on lipogenic
genes expression [23] through a PPARQ-independent pathway.
Another possibility is that TNF-K could increase Id (inhibitor
of DNA binding) 2 and Id 3 protein levels [37], which would
inhibit ADD1 binding to FAS promoter [38].
Based on these results, we have found opposite roles for
ERKs and p38MAPK in the inhibitory e¡ect of TNF-K on
thermogenic and adipogenic di¡erentiation in fetal brown adi-
pocytes. We have also previously found [15] that ERKs were
positive regulators of proliferation and survival, whereas
p38MAPK mediated the TNF-K-induced apoptosis and cell
cycle arrest. Thus, it appears that TNF-K activates di¡erent
signaling pathways with opposite e¡ects on the regulation of
proliferation, di¡erentiation and apoptosis in these cells. This
might have a physiological meaning, related with a tight reg-
ulation of the number of brown adipocytes during develop-
ment, and its di¡erentiation state.
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